B

Evidence from multiple cohorts demonstrates acceptable patient and graft survival in carefully selected HIV-positive recipients treated with modern antiretroviral therapy, indicating that universal exclusion is unwarranted [Stock et al., 2010, PMID 20569301; Sawinski & Bloom, 2019, PMID 30789142].